Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Therapeutic effect of cisatracurium in patients with acute respiratory distress syndrome

Yanping Li¹ , Jiping Li², Zhongmei Ni³

¹Department of Respiratory and Critical Care Medicine, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, 229 Jinhu East Road, Gejiu City, Honghe Prefecture, Yunnan 661000, China; ²Drug Clinical Trials Office, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, 229 Jinhu East Road, Gejiu City, Honghe Prefecture, Yunnan 661000, China; ³Research Service Office, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, 229 Jinhu East Road, Gejiu City, Honghe Prefecture, Yunnan 661000, China.

For correspondence:- Yanping Li Email: 39242728@qq.com Tel:+868732129235

Accepted: 4 October 2023 Published: 31 October 2023

Citation: Li Y, Li J, Ni Z. Therapeutic effect of cisatracurium in patients with acute respiratory distress syndrome. Trop J Pharm Res 2023; 22(10):2171-2176 doi: 10.4314/tjpr.v22i10.19

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the therapeutic effect of cisatracurium, (a neuromuscular blocking agent) in the treatment of acute respiratory distress syndrome (ARDS).

Methods: A total of 94 ARDS patients admitted to The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture ICU from March 2020 to December 2021 were randomly assigned to study and control groups (47 patients each). Both groups received mechanical ventilation, but the study group also received continuous intravenous cisatracurium for 48 h. Health parameters, such as blood gas levels, respiratory mechanics, duration of stay in intensive care unit ICU), mortality rate, and the occurrence of complications, were monitored at 3, 6, and 12 months after treatment.

Results: The study group showed significant improvements compared to control group. Study group also had reduced duration of mechanical ventilation, duration of ICU stay, ICU mortality rate, and incidence of complications (p < 0.05). There were no significant differences in pre-treatment health parameters, but post-treatment, study group had significantly higher levels of blood gas levels and improved lung function (p < 0.05). Study group also had lower scores of illness severity and reduced total mortality rate at 3, 6, and 12 months (p < 0.05).

Conclusion: Administering cisatracurium reduces mechanical ventilation, duration of ICU stay and mortality rate, as well as improves lung function in ARDS patients. Future research involving larger sample size, and takes into consideration regional/environmental differences, is required to validate these findings for reliability.

Keywords: Acute respiratory distress syndrome, Neuromuscular blockade, Cisatracurium, Drug delivery, Treatment, Impact